Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CATCH

Financiado

Novel T cell therapies against lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia globally and can rarely be cured. Despite recent advances, the efficacy of promising autologous T cell-based therapies, such as CAR-T technology and bi-/tri-... ver más

31/12/2023

Academisch Medisch...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-31

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

2 Participantes

Academisch Medisch Centrum A...

150.00K€ | Lider

STICHTING AMSTERDAM UMC

150.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CD20CARNAPT iTANK: a nuniversal technology to boost the efficacy of CAR... 4M€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

SynT Generation, validation and use of a synthetic reporter of CA... 150K€ Cerrado

ArTCell Bottom-up manufacturing of artificial anti-tumor T cells 3M€ Cerrado

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

BOOTCAMP Boosting metabolism in T cells a tool to improve T cell the... 2M€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-06-30
Fecha Fin: 2023-12-31

Líder del proyecto

Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia globally and can rarely be cured. Despite recent advances, the efficacy of promising autologous T cell-based therapies, such as CAR-T technology and bi-/tri-specific antibodies, has been disappointing. This stems from a T cell dysfunction in this disease setting: altered T cell skewing, impaired metabolic plasticity, and disrupted T-cell functioning. Prof. Arnon Kater's group studies alternative activation pathways to overcome T cell dysfunction and stimulate an immune response. CATCH will explore the technical and commercial feasibility of alternative T-cell activation, through CAR-T and tri-specific antibody technologies. To reach proof-of-concept stage, in this project we will: 1) Validate the efficacy of two applications (CAR-T, tri-specific antibody) by achieving T-cell activation and killing target cells in in-vitro CLL samples and live specimens. 2) Perform a thorough IP landscape analysis, establish Freedom-to-Operate, and define an IP strategy. 3) Engage with key stakeholders to gather feedback and advise from key perspectives (patient, clinical, industry), conduct market research to discover potential customers/industrial partners, analyse competitors and identify a feasible roadmap to commercialisation. 4) Formulate a detailed business case to guide the commercialisation of CATCH.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores